Forum for Science, Industry and Business
Sponsored by:     Siemens  n-tv 
Search our Site:

Topic (optional):

 

Home Reports Studies and Analyses Content

Natural Human Hormone as the Next Antidepressant?

next article
11.12.2007

Novel treatment strategies for major depression with broader treatment success or a more rapid onset of action would have immense impact on public health, a new study published in the December 1st issue of Biological Psychiatry explains.

 

This new study reports findings that support the evaluation of a potential new antidepressant agent.


According to the lead author on this study, Kamilla Miskowiak, MSc: “Although depression is often related to problems in the chemistry of the brain, recent evidence also suggests that there may be structural problems as well with nerve cells not being regenerated as fast as normal or suffering from toxic effects of stress and stress hormones.”

This led the researchers to evaluate the effects of erythropoietin (Epo), a hormone naturally produced by the kidneys that stimulates the formation of red blood cells and is known as a treatment for anemia. The authors explain that new evidence shows that Epo also “has neuroprotective and neurotrophic effects in animal models and affects cognitive and associated neural responses in humans,” suggesting that it may be a candidate in the treatment of depression.

In this study, Miskowiak and colleagues evaluated the effects of Epo on the neural and cognitive processing of emotional information in healthy volunteers using functional magnetic resonance imaging (fMRI). They found that Epo regulated the emotional responses of those volunteers that received it, similar to the effects of current antidepressants. Ms. Miskowiak explains that “this finding provides support to the idea that Epo affects neural function and may be a candidate agent for future treatment strategies for depression.”

John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, confirms its potential: “Epo appears to have neurotrophic effects in the brain in animals. The current data suggest that Epo may modulate human brain activity associated with the processing of emotion.

Together, there may now be sufficient evidence to justify evaluating the antidepressant effects of Epo and related compounds in humans.”

Jayne Dawkins | Source: alphagalileo
Further information: www.elsevier.com

next article

More articles from Studies and Analyses:

nachricht Study Shows Sweetener Marketing Tactics May Mislead Consumers
20.11.2009 | Corn Refiners Association

nachricht Debt Stress Drops for Third Straight Month, Survey Finds
20.11.2009 | Ohio State University

All articles from Studies and Analyses >>>

B2B Search

Product / Service
Company / Organisation

Latest News

Scientists Unravel Evolution of Highly Toxic Box Jellyfish

20.11.2009 | Life Sciences

When good companies do bad things: Examining illegal corporate behavior

20.11.2009 | Business and Finance

UCR plant scientist's research spawns new discoveries showing how crops survive drought

20.11.2009 | Agricultural and Forestry Science

VideoLinks

Event News

Multidisciplinary meeting on Urological Cancers aims to benefit cancer patients

20.11.2009 | Event News

'Golden Age' for clinical psychology in Northern Ireland

20.11.2009 | Event News

New Perspectives in Marine Anti-Fouling Research

11.11.2009 | Event News